Saby George - Concepedia

Author

Saby George

Roswell Park Comprehensive Cancer Center ORCID

Also Known As

David Spigel, George, Saby, Hutson, Thomas E., S George, S. George, S.A. George, Saby George, Shone Padinjarethil George

328

Publications

21.5K

Citations

H-Index

Concepts

All Affiliations

Roswell Park Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center Fox Chase Cancer Center The University of Texas MD Anderson Cancer Center Bristol-Myers Squibb (United States)

About

Saby George is an author at Roswell Park Comprehensive Cancer Center specializing in oncology, medicine, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	53	4K
2	Health Sciences	12	13	425
3	Education	1	1	68
4	Biostatistics	1	1	68
5	Cell Biology	1	1	10

Saby George

104

Publications

20.6K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert J. Motzer, Bernard Escudier, Saby George, New England Journal of Medicine	2015	5.8K
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera, New England Journal of Medicine	2018	4.5K
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial Robert J. Motzer, Brian I. Rini, David F. McDermott, Journal of Clinical Oncology	2014	1.1K
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Robert J. Motzer, Brian I. Rini, David F. McDermott, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyImmune Checkpoint Inhibitor	2019	763
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. James R. Berenson, Alan Lichtenstein, Lisa A. Porter, Journal of Clinical Oncology	1998	652
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Journal of the National Comprehensive Cancer Network	2022	627
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, ESMO Open	2020	515
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2018	364
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial Robert J. Motzer, Bernard Escudier, Saby George, Cancer	2020	327
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Lawrence Fong, Andrew Hotson, John D. Powderly, Cancer Discovery	2019	321

Page 1